Issues
-
Cover Image
Cover Image
Obesity increases the risk for breast cancer after menopause. Animal studies reveal that obesity and ovariectomy-induced overfeeding converge to promote progesterone receptor (PR)-positive mammary tumors as shown by high nuclear PR immunohistochemical staining. Elevated PR expression positively correlated with tumor expression of glycolytic and lipogenic enzymes, glucose uptake, and proliferation markers. A similar relationship between PR expression and metabolic capacity was observed in tumors from postmenopausal women. Metformin treatment during the window of weight gain following ovariectomy caused PR downregulation and tumor regression. For details, see article by Giles and colleagues on page 6490. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Epigenome Consortium
A Blueprint for an International Cancer Epigenome Consortium. A Report from the AACR Cancer Epigenome Task Force
Reviews
Priority Report
Paracrine Hedgehog Signaling Drives Metabolic Changes in Hepatocellular Carcinoma
Integrated Systems and Technologies
An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens as Potential Immunologic and Clinical Targets in Cancer
Microenvironment and Immunology
Neuropilin-1 Identifies a Subset of Bone Marrow Gr1− Monocytes That Can Induce Tumor Vessel Normalization and Inhibit Tumor Growth
Molecular and Cellular Pathobiology
miR-23b Represses Proto-oncogene Src Kinase and Functions as Methylation-Silenced Tumor Suppressor with Diagnostic and Prognostic Significance in Prostate Cancer
Therapeutics, Targets, and Chemical Biology
Tumor and Stem Cell Biology
Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer
The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss
Host Immune Defense Peptide LL-37 Activates Caspase-Independent Apoptosis and Suppresses Colon Cancer
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.